GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

If you're already subscriber or thinking of trying meal delivery, these tips and tricks will help you get more for less. David lives in Brooklyn where he's spent more than a decade covering all ...

2024.126294) The study conducted by researchers at the University of Michigan and the U.S. Centers for Disease Control and Prevention and published in the journal Vaccine, evaluated newly approved RSV ...

[34][35][36][37][38][39] The world’s first respiratory syncytial virus (RSV) vaccine for older adults Arexvy is registered for use in Canada, Australia, the US, the UK, the European Union, Japan and ...

Advances in medical research have brought effective RSV vaccines to the market, such as Arexvy and Abrysvo. Neither is an mRNA vaccine, but both vaccines are indicated to prevent RSV in adults. The ...

GSK plc (LSE/NYSE: GSK) has received approval from the European Commission to extend the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults aged 50-59 at increased risk of severe ...

The CDC recommends a single dose of either GSK’s AREXVY, Moderna’s mRESVIA or Pfizer’s ABRYSVO for all adults 75 years and older and adults between the ages of 60 to 74 who are at increased ...

The vaccine has been available for adults over 60 years since June 2023. Credit: MargJohnsonVA/Shutterstock. The European Commission (EC) has authorised GSK’s ...